Yuki Noguchi
speaker
586 appearances
109 recordings
1 series
first heard Feb 2025
last heard 6 Sep
Yuki Noguchi’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 83 in all, peaking in Jul 2026 with 19.
Appearances
It feels like it's so close, and I kind of feel like a ripe tomato on a vine.
It's like if I can just
keep holding on for a little bit longer, this just might work for me.
Yukina Gucci, NPR News.
The drug Deraxanracib is in a class of genetically engineered medicines known as RAS inhibitors.
It identifies and kills pancreatic cancer cells using a genetic mutation common to that cancer.
The drug lengthens patient survival from about two to three months on chemotherapy to eight or nine months on average and has fewer side effects.
Drugs in a similar class have transformed treatment of colorectal and lung cancers.
The new data are so promising, the Food and Drug Administration last week allowed the drug maker, Revolution Medicines, to expand access for pancreatic cancer patients prior to approval.
Yuki Noguchi, NPR News.
So we love talking about pooping until about the age of 12.
And then there's this radio silence.
So we love talking about pooping until about the age of 12.
And then there's this radio silence.
Medicines like Ozempic and Zepbound are intended as lifelong treatments.
But a study shows about three-quarters of people stop using them within a year, while other research shows those who quit intend to later resume taking the drugs.
In other words, people appear to be cycling on and off the drugs.
And indeed, many ads encourage their use as diet aids.
But GLP-1s cause lean muscle loss too, says Texas Tech medicinal chemist Mahmoud Salama Ahmed.
Muscle loss can impair metabolism and balance and lead to fractures.
Showing 261–280 of 586 · page 14 of 30
← Previous
Next →